United States Health

Cardinal Infrastructure Group (NASDAQ:CDNL) reported second-quarter 2026 revenue of $226.9 million, up 114% year over year, with approximately 64% organic growth.

Cardinal Health (NYSE:CAH) reported fiscal fourth-quarter 2026 revenue of $63.7 billion, up 6%, while GAAP operating earnings rose 70% to $729 million.

BioHarvest Sciences (NASDAQ:BHST) reported second-quarter 2026 revenue of $8.8 million, up 3.8%, while gross margin slipped to 58%.

Shattuck Labs (NASDAQ:STTK) reported a $15.2 million Q2 2026 net loss with no revenue while advancing lead candidate SL-325.

Organigram Global (NASDAQ:OGI) reported $145.1 million in third-quarter gross revenue alongside a net income of $105.5 million.

Philips (NYSE:PHG) raised Exor’s permitted ownership cap to 22% from 20% under an updated long-term relationship agreement.

JBS (NYSE:JBS) reported record second-quarter 2026 net sales of $23.9 billion, up 14% from $21 billion a year earlier.

Jazz Pharmaceuticals (NASDAQ:JAZZ) agreed to acquire privately held Actio Biosciences for $820 million upfront, adding the clinical-stage epilepsy candidate ABS-1230 to its rare neurological disease portfolio.

Village Farms (NASDAQ:VFF) reported Q2 2026 consolidated net sales of $64 million, up 7% year over year, as cannabis revenue reached a record $53.5 million.

Axsome Therapeutics (NASDAQ:AXSM) reported Q2 2026 total net product revenue of $218.4 million, up 46% year over year, led by continued growth from AUVELITY.

BeOne Medicines (NASDAQ:ONC) and Revolution Medicines (NASDAQ:RVMD) announced a multi-part oncology collaboration combining clinical research programs with a regional rights agreement covering four RAS(ON) inhibitors in selected Asian markets.

Dole (NYSE:DOLE) reported Q2 2026 revenue of $2.499 billion, up 2.9%, while net income increased to $35.1 million from $18 million.